APJ in Myocardial Infarction- and Hypertension-Induced Heart Failure: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Daniela Rossin
,
Roberto Vanni
,
Marco Lo Iacono
,
Caterina Cristallini
,
Claudia Giachino
,
Raffaella Rastaldo

The widely expressed G protein-coupled apelin receptor (APJ) is activated by two bioactive endogenous peptides, apelin and ELABELA (ELA). The apelin/ELA-APJ-related pathway has been found involved in the regulation of many physiological and pathological cardiovascular processes. Increasing studies are deepening the role of the APJ pathway in limiting hypertension and myocardial ischaemia, thus reducing cardiac fibrosis and adverse tissue remodelling, outlining APJ regulation as a potential therapeutic target for heart failure prevention.

  • apelin
  • ELABELA/Toddler/Apela
  • APLNR/APJ receptor
  • peptide analogue
  • cardiovascular disease
  • myocardial infarction
  • heart failure
  • hypertension
  • angiogenesis
  • fibrosis

1. Introduction

Heart failure (HF) is one of the most common global causes of morbidity and mortality, and its prevalence may rise due to the growing aging population and a variety of risk factors [1]. HF is a chronic clinical syndrome characterized by structural and/or functional cardiac abnormalities, leading to left ventricle (LV) dysfunction. Both hypertension and myocardial infarction (MI) trigger negative cardiac tissue remodelling that, together with the very limited regenerative capacity of cardiac tissue, leads to progressive heart impairment that ultimately compromises cardiac function. The existing HF medications involve surgical and non-surgical techniques used to counteract cardiac deterioration and remodelling, including drug treatments aimed to increase cardiac functionality, decrease hypertension, and/or reduce myocardium extracellular matrix deposition. Although these treatments have decreased the rate of morbidity and mortality, they are, however, uncapable of avoiding ventricular remodelling and progressive fibrosis [2].
The apelin/ELABELA-APJ axis can represent a potential HF therapeutic target and has been shown to play a role in the pathophysiology of both MI and hypertension. However, one of the challenges in using the native apelin and ELABELA (ELA) peptides as therapeutic agents is their short half-life in the blood circulation or extracellular environment.

2. APJ and Its Endogenous Agonists

2.1. APJ

Apelinergic system history began in 1993 with the first description of the apelin receptor (APJ, also known as APLNR) based on its 31% homology with angiotensin II type 1 receptor (AT1R) [3]. Since the homologous sequences are primarily present in the seven hydrophobic transmembrane domains, APJ does not bind to angiotensin II (AngII) and for this reason was considered an orphan receptor for many years. At the same time, tissue distribution of APJ and AT1R is quite similar. APJ is widely expressed in the body and highly expressed mainly in the cardiovascular (CV) system where this receptor is present in cardiomyocytes (CMs), endothelial cells (ECs), and vascular smooth muscle cells (SMCs) [4][5].
The amino acid sequence of this receptor is made of 377 amino acid residues and is well conserved; in fact, the human APJ gene (APLNR) located on chromosome 11q12 displayed more than 90% sequence homology to murine APJ [6]. N-terminal glycosylation of APJ is essential for the proper receptor’s stability, protein folding, and binding to the ligand, while C-terminal palmitoylation favours the association to the cell membrane. Moreover, palmitoylation combined with phosphorylation allows APJ internalisation, dimerization, and the interaction with ligands [7]. APJ is a G-protein-coupled receptor (GPCR), and G proteins are formed by three different subunits (α, β, and γ) and are classified according to the α subunit in four families (i.e., Gαi/o, Gαq/11, Gαs, and Gα12/13) that trigger several different signalling pathways [8]. Upon C-terminal phosphorylation of APJ by GPCR kinases, β-arrestin is recruited and inhibits APJ activation by promoting its internalization [9]. It is also interesting to note that in the heart APJ may act as a mechanosensor for stretch through recruitment of β-arrestin [10].
The role of APJ resulted as pivotal in the cardiovascular system. During embryogenesis, APJ is expressed in mesoderm and APJ deficiency-caused defects in coronary vessel development [11][12]. In adults, APJ activation led to vasodilatation resulting in lowered blood pressure, angiogenesis, haemostasis, and anti-thrombotic effects. In the heart, it increases conduction velocity within CMs, has antiarrhythmic properties, and reduces myocardial hypertrophy and fibrosis [8].
APJ expression increases after ischaemia through the hypoxia-inducible factor-1 (HIF-1a) pathway [13].

2.2. Apelin

Apelin was the first discovered natural endogenous ligand of APJ. Apelin was initially isolated from a cow’s stomach in 1998 by Tatemoto and co-workers [14], and afterwards, the presence of apelin mRNA has been detected in numerous tissues and organs, including adipose tissue, brain, liver, kidneys, skeletal muscles, heart, vessels, and lungs [15][16][17]. Apelin is encoded by a gene located on chromosome Xq 25–26 in various animal species including humans, mice, rats, and cows [16]. Apelin is initially produced as a preproprotein containing 77 amino acids, with the active sequence located in the C-terminal region. The removal of 22-unit signal peptide from N-terminal preproprotein generates the proprotein, also known as apelin-55 [18]. Endopeptidases further cleave apelin-55 into bioactive isoforms called apelin-36, -17, or -13, accordingly to the number of amino acid residues (Figure 1). Among them, the shorter peptides apelin-17, -13, and the pyroglutamate modified form of apelin-13 called [Pyr1]-apelin-13 have a higher affinity for APJ [14], while fragments shorter than 10 amino acids are biologically inactive [19]. Difference in isoform distribution was also observed; for example, [Pyr1]-apelin-13 is predominant isoform in the heart and plasma due to its resistance to degradation by peptidases [20][21], while apelin-36 is mainly detected in the lung, testis, and utero [22].
Figure 1. Amino acid sequence of apelin and ELABELA (ELA) peptides. (a) Schematic representation of apelin-13, apelin-17, apelin-36, and [Pyr1]-apelin-13 that may all be produced by further processing of apelin-55; all the isoforms have the ability to bind APJ. Angiotensin-converting enzyme type II (ACE2), furin (also known as PCSK3), kallikrein (KLK1), and neprilysin (NEP) degrade native apelin isoforms, thus affecting their bioavailability; (b) Schematic representation of ELA peptide maturation by furin convertase to generate ELA-21 and ELA-11 fragments. Disulfide bridges are shown as light blue lines.
Apelin isoforms display a brief half-life in vivo, lasting less than 5 min [23][24] due to their rapid breakdown by different proteases. Angiotensin converting enzyme II (ACE2) is a carboxypeptidase that was firstly identified as apelin-degrading enzyme. ACE2 cleaves the Pro12–Phe13 peptide bond at C-terminal level, generating inactive apelin isoforms [22][25][26]. Later, other two cleavage sites within the apelin sequence were identified in apelin-13: Arg4–Leu5 and Leu5–Ser6 at C-terminus (RPRL motif), which are cleavage sites of a zinc-dependent metalloprotease called neprilysin (NEP) [27], thus abolishing apelin binding to APJ [28]. Recently, prolyl carboxypeptidase (PRCP), another protease capable to hydrolyse [Pyr1]-apelin-13, has been identified in endothelial cell membrane [29] while the action of plasma serine protease kallikrein B1 (KLKB1) on the first three N-terminal residues of apelin-17 result in the production of an inactive C-terminal 14-mer [30].
Apelin/APJ axis plays a pivotal role in maintaining CV homeostasis [8][31].
In healthy humans, plasma apelin account for 0.26 ± 0.03 nmol/L concentration, and this low level would suggest a paracrine and autocrine activity [32]. However, hypoxia conditions may raise the plasma level of apelin, and this synthesis is mediated by HIF-1 binding to the apelin gene [33][34][35].

2.3. ELABELA

The discrepancy found in the foetal phenotypes between apelin knock-out and APJ-deficient mice, with observation of improper cardiac vessel formation and prenatal mortality, respectively, later led to the identification of Apela/ELABELA/Toddler (hereafter referred to as ELA) as a second APJ ligand [36][37].
It is encoded by the Apela/ELABELA/Toddler gene on chromosome 4q32.3, which is activated since the early embryonic stage. Apela gene encodes 54 amino acids pre-proprotein from which the active peptides ELA-32, -22, -21, and -11 (referring to the number of remaining amino acid residues at the C-terminus) are generated [36][38] (Figure 1). The C-terminal 13 residues of ELA are highly conserved across species and are required for APJ binding and the consequent activation of Gi protein alpha subunit (Gαi) as well as β-arrestin signalling pathways [38][39].
ELA-32 and ELA-11 differ in their membrane-interactive properties, providing a potential mechanism for distinctive signalling outcomes [40].
ELA is highly expressed in embryos, but is also present in some adult tissues, i.e., heart and blood vessels [32][41][42]. Like apelin, ELA displays a short half-life in plasma, and furins have been proposed as possible proteases able to cleave ELA-55 in two conserved di-arginine motifs [37][38].
The absence of the ELA gene causes early abnormalities in heart development, as observed in APJ-knockout animals [37], thus highlighting a crucial role of ELA in cardiac development and also leading to suggest a potential role of ELA in cardiac regeneration. In the rodent heart, ELA is predominantly expressed in the non-CM fraction, suggesting that ELA expression mainly occurs in fibroblasts and endothelial cells [42]. Paracrine and autocrine activities were suggested because of its low plasma level in humans (0.34 ± 0.03 nmol/L) [32], while in mouse heart, samples obtained 4 weeks after MI ELA expression resulted enhanced in the left ventricle of about 6 folds compared to control [42].
Due to the rather recent discovery of ELA, there is still much to find out about its endogenous isoform functions and their interaction with APJ.

2.4. Physiological Ligand Activities in CV System

The apelin/ELA-APJ pathway is already involved in the embryonic heart development, even though the two endogenous ligands take part to this process at different time points or areas of the foetal heart as already reviewed by Kuba and co-authors [43]. In the adult CV system, upon binding to the APJ receptor, apelin and ELA exert mostly similar biological effects.
After APJ binding, both apelin and ELA, at nanomolar concentration, exert positive inotropic effect on the in vivo rat hearts with comparable enhancement in the maximal rate of rise of left ventricular pressure (dP/dtmax), fractional shortening (c), heart rate, and cardiac output. Moreover, they reduce both left ventricular end diastolic pressure (LVEDP) and left ventricular end systolic pressure (LVESP), the latter likely due to a reduction of afterload (i.e., the resistance to cardiac output) caused by vasodilation [32][38][44]. Apelin expression appeared to be crucial for proper heart function as proved by the studies of Kuba and colleagues where the lack of apelin gene caused systolic dysfunction and the gradual decline in cardiac contractility, despite the absence of histological abnormalities [45]. Apelin-induced increase in contractility was extensively studied and showed the involvement of several pathways, among which the activation of pro-survival kinases PKC and ERK1/2 that favour the opening of sodium (NHE-1) and Ca2+ (NCX) channels [46][47]. Regarding ELA-dependent inotropic effects, ELA-32 was studied by Perjés and colleagues who attributed the increase in contractility to MEK1/2-ERK1/2 but not to PKC, whereas the apelin inotropic effect was mediated by both ERK1/2 and PKC [42]. However, the ELA-mediated inotropic effect was not completely suppressed after the inhibition of the MEK1/2–ERK1/2 pathway [42], thus suggesting that other additional pathways can be activated by this peptide. Further investigation will be needed to clarify this issue. Remarkably, in the healthy hearts, apelin treatment exerted a moderate inotropic effect that only lasted few minutes, while the inotropic effect resulted as particularly marked when administered in failing hearts [48][49].
More recently, a significant increase in lusitropic effect in response to apelin treatment was observed in mouse apelin knock-out CMs [50]. Apelin-induced positive lusitropic effect can be attributed to the preservation of SERCA activity avoiding the enhancement of intracellular calcium level, which may cause calcium overload-induced arrhythmogenesis [50][51].
Apelin and ELA are also vasoactive peptides with different mechanisms of action. Their administration results in a reduction in vascular resistance with consequent increase in blood flow accompanied by arterial pressure decrease. Apelin usually induces endothelial-induced vasodilation mediated by NO release via Akt activation [23][52][53], while in the case of endothelial disfunction, the peptide acts directly on smooth muscle cells triggering the opposite effect [54][55]. On the contrary, ELA-induced vasorelaxation did not require NO release [37]. Recently, the mechanisms of ELA-induced vasodilation have been elucidated by Sahinturk and collaborators who reported that endothelial-dependent vasorelaxation is mediated by prostanoids, while AMPK, PKC, and calcium-activated potassium channel activation was observed in the endothelial-independent pathway [56]. It is likely that beside the apelin/ELA-mediated increase in contractility, these peptides improved cardiac function by inducing vasodilation. In fact, the lowered afterload and the increased venous return (preload) allowed the heart to enhance the stroke volume. These APJ ligand effects can be useful in hearts with progressive function deterioration.
Notably, both peptides are involved in the angiogenic process (see below). Moreover, their ability to attract and promote migration of endothelial cells led to consider apelin and ELA as chemotactic peptides in the angiogenic process [57][58].
APJ knockout mice exhibit abnormal body fluid balance [59] demonstrating the involvement of apelin and ELA in water homeostasis. Indeed, they reduce water intake, and apelin also increases water excretion [60][61]. Moreover, apelin also resulted as involved in energy metabolism by increasing glucose uptake by tissue cells and insulin sensitivity and mitochondrial bioactivity, as recently reviewed by Hu and collaborators [60].

3. Cardioprotective Role of APJ Endogenous Ligands

In recent years, a growing body of evidence has highlighted the potential of apelin and ELA as therapeutic targets for the treatment of CV diseases, such as hypertension, ischaemic heart disease, and heart failure.

3.1. Protection against Hypertension

Hypertension is a chronic medical condition in which the long-term high arterial blood pressure represents a relevant variable risk factor for cardiovascular disease morbidity and mortality because of increased incidence of MI and heart failure development [62][63]. Indeed, the persistence of high blood pressure induces LV hypertrophy and remodelling as adaptive response to cardiac output resistance [64].
The renin–angiotensin system (RAS) is a key pathway in the development and progression of hypertension. AngII, upon binding to AT1R, exerts a vasoconstrictor effect that plays a physiological role in arterial blood pressure control through the RAS. However, AngII–AT1R axis hyperactivation commonly leads to development and progression of hypertension [65]. AngII is formed starting from liver-produced angiotensinogen precursor which is cleaved by renin into Angiotensin I which in turn is converted to AngII through the catalytic activity of the angiotensin converting enzyme (ACE). Conversely, ACE2 negatively regulate RAS through the conversion of AngII into Ang(1–7), resulting in blood pressure reduction [66].
The apelin/ELA-APJ system can affect hypertension counteracting RAS (Figure 2).
Figure 2. ELABELA and apelin protect against hypertension counteracting the renin-angiotensin II system (RAS) with different mechanisms. Angiotensin Converting Enzyme (ACE) converts Angiotensin I (AngI) to Angiotensin II (AngII), which binds Angiotensin II Receptor Type 1 (AT1R) and induces vasoconstriction, leading to hypertension. Endogenous ELABELA and apelin neutralize AngII-induced vasoconstriction through their direct vasodilator effect. Both ligands exert vasodilation through AngII level reduction: ELABELA downregulates ACE expression, limiting AngII production, while apelin boosts the expression of ACE2 which hydrolyzes AngII to Ang(1–7). The binding of apelin to its receptor APJ leads to the heterodimerization of APJ and AT1R, decreasing the AT1R availability for binding AngII, thus inhibiting the AngII-AT1R signalling pathway that leads to hypertension.
Indeed, apelin/ELA and AngII exerted an opposite effect on vessels. In this regard, it has been reported that administration of either apelin or ELA had a blood pressure-lowering effect, potentially indicating a therapeutic role of these peptides in reverting hypertension, thus reducing the risk of developing HF [67][68]. In addition, apelin is capable of boosting ACE2 expression, and this is another mechanism by which it counteracts RAS. In fact, Sato and colleagues pointed out that apelin improved ACE2 promoter activity in neonatal CMs in a dose-dependent manner [69]. In line with the in vitro results, apelin KO mice also showed downregulation of ACE2 expression and, consequently, low ACE2 protein level [69][70]. Of note, ACE2, which primarily acts on AngiII, has a role in apelin metabolism because it can cleave apelin into inactive isoforms, though it is unable to degrade ELA [23][66][67]. Conversely, ELA did not affect ACE2 expression, but it reduced angiotensin-induced blood pressure via downregulation of ACE expression.
Another apelin mechanism opposing RAS consists of heterodimer formation by APJ and AT1R interaction, resulting in inhibition of AngII binding to its receptor and signalling pathway activation [71].
Protracted hypertension induces remodelling of the heart which consists of cardiac hypertrophy and deposition of collagen fibres between the CMs, namely interstitial fibrosis. This morphological alteration also contributes to cardiac dysfunction, and indeed, CMs develop hypertrophy as adaptation to elevated cardiac workload, with the aim of maintaining left ventricle ejection fraction (LVEF) unchanged, at least at the beginning of the pathological condition. This protracted cardiac remodelling can give rise to arrhythmogenesis and HF over-time [72].
The link between the apelinergic pathway and AngII RAS pathways was studied in apelin−/−mice through subcutaneous infusion with AngII for two weeks. AngII treatment caused increased cardiac dysfunction, hypertrophy, and fibrosis and enhanced ACE/ACE2 as well as TGF-β expression in apelin−/−compared to WT mice [73]. It was also observed that the loss of apelin facilitated AngII-induced injury pathways, leading to enhanced pathological hypertrophy and myocardial fibrosis [70][74]. Furthermore, apelin-deficient mice showed downregulation of ACE2, increased superoxide production, and augmented NADPH oxidase activity [70].
In another animal model, AngII-induced hypertension yielded an increase in myocardial fibrosis and inflammation. Moreover, AngII lowered apelin and ELA levels in both rat and primary neonatal rat cardiac fibroblasts, and these results were in line with the low level of these peptides in hypertension patients [75]. The adverse remodelling was shown to be mediated by miR-122p, as the treatment of primary neonatal rat cardiac fibroblasts with both AngII and the inhibitor of miR-122p abolished the AngII-induced downregulation of APJ ligands [75]. Interestingly, pre-treatment of cardiac fibroblasts with apelin or ELA prevented the enhancement of inflammation and fibrosis markers. These authors also highlighted a link between APJ ligand level and cardiac fibrosis [75].
On the other hand, the animal treatment with apelin-13 could counteract AngII-induced fibrosis via TGF-β1/SMAd2/α-SMA and preserved the homogeneity of electrical conduction [76].
In in vivo studies, the AngII-dependent ELA reduction increased cardiac hypertrophy, fibrosis, and dysfunction in murine heart, while ELA administration reduced cardiac fibrosis, ultrastructural injury, lipid peroxidation, and inflammation, thus improving cardiac function [77]. Moreover, ELA mice administration for two weeks after transaortic constriction (TAC) promoted ACE expression downregulation and reduced cardiac fibrosis, promoted the maintenance of FS rate, and suppressed the expression of cardiac hypertrophy markers, such as BNP, ANF, and β-Myhc [78].
Notably, ELA and apelin circulating levels were found decreased in patients with hypertension [79][80][81]. Additionally, Baysal and colleagues discovered that hypertensive individuals with impairment in left ventricular systolic and diastolic performance displayed low plasma apelin level that increased following one month of antihypertensive medication [82]. Further, concerning the ELA level, it was observed that reduced ELA plasma concentration was associated with atrial fibrillation in hypertensive patients [83]. Among the HF patients, those with higher level showed a more preserved LVEF and better outcomes [84]. Furthermore, low apelin and ELA expression was found in patients with pulmonary arterial hypertension [32].
Taken together, these findings suggest that APJ ligands have significant potential as therapeutic strategy to counteract hypertension and the related complications (Figure 3).
Pharmaceutics 15 01408 g003 550
Figure 3. Dual mechanism of ligand-activated APJ in reducing hypertension-induced heart failure. The figure illustrates the two ways in which APJ activation can reduce cardiac overload-induced heart failure. Firstly, by reducing renin-angiotensin system (RAS) activation, APJ lowers blood pressure, thus decreasing cardiac afterload. Secondly, activated APJ directly acts on the heart, decreasing the risk of developing arrhythmias chronic inflammation, interstitial fibrosis, and cardiac hypertrophy, leading to improved cardiac function.

3.2. Protection against MI

MI is a critical cardiovascular event associated with high morbidity and mortality in which blood flow blockade prevents the O2 supply to the cardiac tissue. The restoration of blood flow, via thrombolytic therapy, primary percutaneous coronary intervention, and coronary artery bypass grafting (CABG), is essential for cardiac tissue salvage. However, after reperfusion, an exacerbation of myocardial damage takes place. For this reason, it is more correct talking of ischaemia-reperfusion (I/R) injury that consists of a series of events including cell death, inflammation, oxidative stress, calcium overload, and paradoxical pH that lead to cardiac tissue damage as well as impaired heart function (i.e., stunning of myocardium) [85]. Notably, it has been estimated that about 30% of patients develop I/R injury which seriously affected patient prognosis [85][86].

4. APJ Peptide Agonists

Modified peptides can be designed to specifically bind a target receptor. Peptide modifications might modulate protein–protein interactions to improve target selectivity and affinity that play crucial roles during the persistent interaction between proteins. Furthermore, compared to small molecules and antibodies, modified peptides have the important advantage of causing a minor immune response [87]. The small size of APJ peptide ligands makes them easy to manipulate.

4.1. APJ Endogenous Ligand Main Chain Modifications

The well-known short in vivo half-life that characterises both apelin and ELA poses a hurdle to their clinical translation. Many studies thus aim to develop more stable APJ ligands, based on either apelin or ELA peptide structure, through many different approaches, such as main-chain residue removal/addition, palmitoylation, and cleavage site modification of the several proteases involved in the degradation of parental peptides to obtain longer half-life in blood circulation as well as in tissues, trying to maintain at the same time apelin- or ELA-like cardiovascular effects (Table 1 and Table 2).
Table 1. Main chain modifications of APJ ligands, based on [Pyr1]-apelin-13, apelin-12, apelin-17, or ELA peptide, and their effects on stability, binding affinity, and cardiovascular properties.

APJ Ligand

Substituted Residues

Introduced Residues

Effects

Ref

[Pyr1]-apelin-13

Leu5, Ser 6

-

↑ plasma protein stability

[88]

Phe13

[(L-α-Me) Phe]

↓ Pro12-Phe13 hydrolisis

Pro12-Phe13

conformational constrained amino acids

↑ binding affinity

↑ plasma protease stability

[89]

Aia -Phe

1Nal-α,α-dibenzylglycine

↑ Gα12 pathways

↑ affinity and resistance to ACE2 cleavage

↑ in vitro and in vivo

pharmacokinetics

[90]

Phe13

phenyl groups at the ortho-, meta-, and para-positions of Phe13

slight effect on APJ binding affinity

(L-α-Me) Phe or p-benzoyl-L-Phe (Bpa)

↑ APJ functional selectivity for

Gαi proteins

no effect on cardiac contractility

in healthy rats

↑ binding affinity vs. [Pyr1]-apelin-13

↑ resistance to ACE2 cleavage

↓ hypertrophy and fibrosis

[91]

N-Teminus (pGlu)

palmitic acid,

(at Pro12) Aib, Nle

↑ half-life (29 h in rat plasma)

[92]

N-Terminus

Alkylated dipeptide

↑ affinity in the low nM range

[93]

extended and bulkier substituents

binding affinity close to

[Pyr1]-apelin-13

↓ signalling potency for the

β-arrestin 2 pathway

C-Terminus

positive charge

binding affinity close to [Pyr1]-apelin-13 partial agonism for

β-arrestin2 recruitment

1NaI12

amino-indoloazepinone-Orn

↑affinity for APJ

↑ Gαi1 activation,

↑ stability

↓ hypotensive effects

apelin-12

N-terminus

Met10

(NαMe) Arg

Nle10

↑ proteolytic stability

↑ cardiac function

↓ membrane damage

[94][95]

apelin-17

Classical substituted

P92

↑ plasma half-life

sub-nanomolar affinity for APJ

APJ internalization

↑ diuresis

↓ arterial blood pressure

[96]

LIT01-196

fluoroaddiction

N-terminal

↓ blood pressure in normotensive and hypertensive rats

[97]

Arg, Leu

azapeptides

↑ proteolytic stability vs. NEP

[98]

l-hArg, l-Cha

-

↑ proteolytic stability vs. NEP

prolonged lowering blood pressure effect in mice

[99]

N-terminus

palmitoylation

PEGylation

↑ plasma peptide half-life

↓ blood pressure in mice

[30]

aromatic head groups

carbonate analogues

↑↑ proteolytic stability

[100]

ELA

Pro32

Tyr (OBn), Bpa, or 1Nal

↑ binding affinity vs.

ELA

[101]

N-terminus

pyroglutamic acid (Pyr) residue to ELA(19-32)

↓ arterial pressure

↓ inotropic effects

on the heart

↑ half-life

[38]
Table 2. Peptides obtained by apelin cyclization and their effects on plasma stability, binding affinity, and cardiovascular properties.

Cyclized Peptide

Modified Residues

Cycle Position

Effects

Ref

MM07

N-terminus

N-terminal cycle (MM07)

↑ vasodilatation

↑ cardiac function vs. [Pyr1]-apelin-13

[24]

↑ cardiac function

↓ hypertrophy

[102]

Macrocycle analogues

G-P-M−P-F

[X-P-Nle-P-X]

[B1-P-Nle-P-X]

[B1-P-Nle-P-Xd]

↑ plasma peptide half-life

↑ binding affinity vs.

apelin-13

powerful modulators of cardiovascular system

[89]

C-terminal

C-thermal exocyclic residues

endocyclic residues

↑ G-protein activation on

over-arresting signalling

binding affinity close to [Pyr1]-apelin-13

[103]

Internal position

β alanine spacer

Same APJ affinity of apelin-13

↓ hypotensive effect similar to apelin-13

apelin-13′s His8 position

Nγ-allyl-Nγ-nosyl-α,γ-diamino-butanoic acid

Nπ-allyl-histidine linker

↑ binding affinity

↑ potency

[104]

4.2. Antibody-Based/Bound APJ Agonists

Antibodies are widely used as therapeutic agents due to their ability to recognize and bind to specific receptors with high specificity and affinity. Nowadays, monoclonal antibodies have been utilized successfully in clinical treatment, despite the possibility of causing adverse immune-related reactions (Table 3).
Table 3. Antibody based/bound APJ agonists and their effects on plasma stability, binding affinity, and cardiovascular properties.

Agonist

Substituted Residues

Introduced Residues

Effects

Ref

JN241-9

between E104

and S105 to JN241

tyrosine

agonist activity for cAMP

β-arrestin recruitment

[105]

MM202 (apelin-modified)

Met

Nle and

Fluroaddition-C-terminal

high binding affinity vs [Pyr1]-apelin-13

= or ↑ potency

than

[Pyr1]-apelin-13

[106]

MM202-AlbudAb

  

= or ↑ potency

than

[Pyr1]-apelin-13

MM202 and

AlbudAb fusion

↑ cardiac function

↓ heart rate

Fc-ELA-21

-

Fc and ELA fusion

↑ angiogenesis

↓ apoptosis

↑ cardiomyocyte

proliferation

↓ heart fibrosis

[107]
In a recent study, researchers compared the structure of JN241 APJ-antagonist to that of the potent peptide agonist AMG3054 and generated a panel of JN241 mutants to convert JN241 from antagonist to agonist. Based on this evidence, authors hypothesized that the introduction of amino acids containing aromatic rings could fix the missing hydrophobic interactions and convert JN241 from antagonist to agonist. The tyrosine insertion between E104 and S105 in CDR3 of JN241 converted JN241 to a full agonist (JN241-9) with an EC50 of 36 and 47 nM in the cAMP assay and β-arrestin recruitment assay, respectively. Direct mutation of E104 or S105 to tyrosine or phenylalanine had no effect on antagonist-to-agonist conversion. Molecular modelling and simulation of APJ with JN241 or JN241-9 showed how the inserted tyrosine introduced additional hydrophobic interactions with APJ sub pocket residues, leading to an outward movement of TM6 as an early receptor activation event [105].
Antibody modifications can be considered to enhance the binding affinity, specificity, and stability of the antibody and to optimize its pharmacokinetic and pharmacodynamic properties for therapeutic applications.
Previously, the genetic fusion of human Domain Antibodies (dAbs) with serum albumin (AlbudAbs) was reported to increase the in vivo half-life of recombinant proteins [108]. MM202 is an apelin-modified APJ agonist conserving sequence similarity and functionality of endogenous apelin. MM202 and MM202-AlbudAb conjugate had high binding affinity to the human APJ and displayed functional activity in cell-based signalling assays, with either similar or greater potency than [Pyr1]-apelin-13. Both AlbudAb and MM202-AlbudAb conjugate bound to immobilized human serum albumin with high nanomolar affinity. In an acute cardiovascular study, the MM202-AlbudAb conjugate produced robust cardiovascular responses in normotensive male Sprague Dawley rats, including a reduction in left ventricular systolic pressure, an increase in cardiac contractility, and a decrease in heart rate [106].
The IgG-Fc-ELA protein fusion could also represent a therapeutic option for heart failure. Cardioprotective effects of IgG-Fc-ELA-21 fusion proteins were compared to those of parental peptide. Researchers found that the Fc-ELA-21 was expressed intact in transduced HEK293 cells, without the known furin proteinase-dependent ELA cleavage between position 22 and 23, displaying a half-life of approximately 44 h in mice after subcutaneous injection. The fusion protein showed significant improvements in heart function in rats after 4 weeks of daily injections. Rat treatment with the Fc-ELA-21 fusion protein increased angiogenesis, improved CM proliferation, and reduced apoptosis and heart fibrosis in the infarct area. In comparison, ELA-21 had a half-life of only 13 min and had no significant cardioprotective effects [107].
Lack of human clinical data on agonist peptides emphasizes the need for further research on the safety and efficacy of this promising approach as a new pharmacological option for cardiovascular disease treatment.

4.3. Side Effect and Delivery Issues

While the chemotactic and angiogenic activities of the native apelin and ELA peptides may have important implications in post-MI-related heart failure, they might, however, be detrimental in other conditions such as tumour growth [109]. In fact, it is noteworthy that the signalling pathways triggered in cardioprotection (i.e., MAPK and PI3K/AKT/mTOR) are also involved in cancer growth [110]. Moreover, more research is also needed in order to assess the potential renal and hormonal effects of APJ exogenous agonists, particularly if administered systemically. In fact, apelin reduces water reabsorption by acting at a central and renal level. In this context, plasma apelin and antidiuretic hormone (ADH) are inversely regulated for the maintenance of body fluid homeostasis. In the brain, apelin inhibits the release of ADH into the bloodstream from the posterior pituitary, while in the kidney, apelin regulates renal microcirculation and counteracts ADH-mediated water reabsorption in the collecting duct [111].
The systemic administration of both native and analogue APJ ligands may thus be potentially dangerous. Additionally, the successful outcome of conventional systemic APJ ligand administration procedures is hampered by various issues including the absence of targeting capability to affected sites, poor control of sustained delivery along the necessary therapeutic time, the need for a high peptide concentration at the target site, and possible peptide instability. These peptides could be rather delivered using engineered nanotechnologies as drug delivery systems [112][113]. In this context, Serpooshan and colleagues already performed in 2015 a [Pyr1]-apelin-13 nanodelivery by using a liposomal nanocarrier system, and the intraperitoneal injection of [Pyr1]-apelin-13 nanocarriers prevented cardiac disfunction in a TAC mouse model. In comparison to the commercially available [Pyr1]-apelin-13, such nanocarriers incorporating PEG polymer exerted significantly increased apelin delivery and sustained release both in vitro and in vivo [114]. Similarly, nanotechnologies may be advantageous also for analogue molecule delivery.
Since primary cardiac tumours are exceptionally rare, nanotechnologies and /or biomaterials can also be exploited for the in situ release of APJ analogues, allowing the use of lower dosages compared to systemic administration, causing minor plasma fluctuations, and reducing adverse effects [115]. In a recent study, a microporous annealed particle drug-delivery hydrogel, able to assemble once injected into the heart of infarcted rats forming a porous scaffold, showed promising positive effects in the field of heart regeneration. However, this hydrogel requires a longer-term study as it showed only partial degradation in vivo after 5 weeks [116]. These notes provide the rationale to promote the development of drug-delivering materials able to degrade over time, such as bioresorbable scaffolds, in order to reduce side effects [117]. Despite nanotechnologies and biomaterials are promising therapeutic tools, they still have some limitations due to high costs and safety problems [118].
The use of local administration and biomaterial-mediated controlled analogue release may represent a strategy to overcome potential systemic side effects, allowing in situ molecule delivery and reduction of treatment dosage. Additionally, the use of APJ ligand-derived analogues may have the advantage of low production costs and reduced immune response risks.

This entry is adapted from the peer-reviewed paper 10.3390/pharmaceutics15051408

References

  1. Subramaniam, A.V.; Weston, S.A.; Killian, J.M.; Schulte, P.J.; Roger, V.L.; Redfield, M.M.; Blecker, S.B.; Dunlay, S.M. Development of Advanced Heart Failure: A Population-Based Study. Circ. Heart Fail. 2022, 15, e009218.
  2. Friedman, S.L. Fighting Cardiac Fibrosis with CAR T Cells. N. Engl. J. Med. 2022, 386, 1576–1578.
  3. O’Dowd, B.F.; Heiber, M.; Chan, A.; Heng, H.H.; Tsui, L.C.; Kennedy, J.L.; Shi, X.; Petronis, A.; George, S.R.; Nguyen, T. A Human Gene That Shows Identity with the Gene Encoding the Angiotensin Receptor Is Located on Chromosome 11. Gene 1993, 136, 355–360.
  4. Kleinz, M.J.; Skepper, J.N.; Davenport, A.P. Immunocytochemical Localisation of the Apelin Receptor, APJ, to Human Cardiomyocytes, Vascular Smooth Muscle and Endothelial Cells. Regul. Pept. 2005, 126, 233–240.
  5. Zhang, Z.; Tang, J.; Song, J.; Xie, M.; Liu, Y.; Dong, Z.; Liu, X.; Li, X.; Zhang, M.; Chen, Y.; et al. Elabela Alleviates Ferroptosis, Myocardial Remodeling, Fibrosis and Heart Dysfunction in Hypertensive Mice by Modulating the IL-6/STAT3/GPX4 Signaling. Free Radic. Biol. Med. 2022, 181, 130–142.
  6. Wu, Y.; Wang, X.; Zhou, X.; Cheng, B.; Li, G.; Bai, B. Temporal Expression of Apelin/Apelin Receptor in Ischemic Stroke and Its Therapeutic Potential. Front. Mol. Neurosci. 2017, 10, 1.
  7. Dawid, M.; Mlyczyńska, E.; Jurek, M.; Respekta, N.; Pich, K.; Kurowska, P.; Gieras, W.; Milewicz, T.; Kotula-Balak, M.; Rak, A. Apelin, APJ, and ELABELA: Role in Placental Function, Pregnancy, and Foetal Development—An Overview. Cells 2021, 11, 99.
  8. Chapman, N.A.; Dupré, D.J.; Rainey, J.K. The Apelin Receptor: Physiology, Pathology, Cell Signalling, and Ligand Modulation of a Peptide-Activated Class A GPCR. Biochem. Cell Biol. 2014, 92, 431–440.
  9. Chen, J.; Chen, X.; Li, S.; Jiang, Y.; Mao, H.; Zhang, R.; Ji, B.; Yan, M.; Cai, X.; Wang, C. Individual Phosphorylation Sites at the C-Terminus of the Apelin Receptor Play Different Roles in Signal Transduction. Redox Biol. 2020, 36, 101629.
  10. Scimia, M.C.; Hurtado, C.; Ray, S.; Metzler, S.; Wei, K.; Wang, J.; Woods, C.E.; Purcell, N.H.; Catalucci, D.; Akasaka, T.; et al. APJ Acts as a Dual Receptor in Cardiac Hypertrophy. Nature 2012, 488, 394–398.
  11. D’Aniello, C.; Fiorenzano, A.; Iaconis, S.; Liguori, G.L.; Andolfi, G.; Cobellis, G.; Fico, A.; Minchiotti, G. The G-Protein-Coupled Receptor APJ Is Expressed in the Second Heart Field and Regulates Cerberus–Baf60c Axis in Embryonic Stem Cell Cardiomyogenesis. Cardiovasc. Res. 2013, 100, 95–104.
  12. Sharma, B.; Ho, L.; Ford, G.H.; Chen, H.I.; Goldstone, A.B.; Woo, Y.J.; Quertermous, T.; Reversade, B.; Red-Horse, K. Alternative Progenitor Cells Compensate to Rebuild the Coronary Vasculature in Elabela- and Apj-Deficient Hearts. Dev. Cell 2017, 42, 655–666.e3.
  13. He, L.; Xu, J.; Chen, L.; Li, L. Apelin/APJ Signaling in Hypoxia-Related Diseases. Clin. Chim. Acta 2015, 451, 191–198.
  14. Tatemoto, K.; Hosoya, M.; Habata, Y.; Fujii, R.; Kakegawa, T.; Zou, M.-X.; Kawamata, Y.; Fukusumi, S.; Hinuma, S.; Kitada, C.; et al. Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor. Biochem. Biophys. Res. Commun. 1998, 251, 471–476.
  15. Liu, J.; Liu, M.; Chen, L. Novel Pathogenesis: Regulation of Apoptosis by Apelin/APJ System. Acta Biochim. Biophys. Sin. 2017, 49, 471–478.
  16. Kawamata, Y.; Habata, Y.; Fukusumi, S.; Hosoya, M.; Fujii, R.; Hinuma, S.; Nishizawa, N.; Kitada, C.; Onda, H.; Nishimura, O.; et al. Molecular Properties of Apelin: Tissue Distribution and Receptor Binding. Biochim. Et Biophys. Acta (BBA)-Mol. Cell Res. 2001, 1538, 162–171.
  17. De Falco, M.; De Luca, L.; Onori, N.; Cavallotti, I.; Artigiano, F.; Esposito, V.; De Luca, B.; Laforgia, V.; Groeger, A.M.; De Luca, A. Apelin Expression in Normal Human Tissues. In Vivo 2002, 16, 333–336.
  18. Shin, K.; Pandey, A.; Liu, X.-Q.; Anini, Y.; Rainey, J.K. Preferential Apelin-13 Production by the Proprotein Convertase PCSK3 Is Implicated in Obesity. FEBS Open Bio. 2013, 3, 328–333.
  19. Zhang, Y.; Maitra, R.; Harris, D.L.; Dhungana, S.; Snyder, R.; Runyon, S.P. Identifying Structural Determinants of Potency for Analogs of Apelin-13: Integration of C-Terminal Truncation with Structure–Activity. Bioorg. Med. Chem. 2014, 22, 2992–2997.
  20. Murza, A.; Belleville, K.; Longpré, J.-M.; Sarret, P.; Marsault, É. Stability and Degradation Patterns of Chemically Modified Analogs of Apelin-13 in Plasma and Cerebrospinal Fluid. Biopolymers 2014, 102, 297–303.
  21. Zhen, E.Y.; Higgs, R.E.; Gutierrez, J.A. Pyroglutamyl Apelin-13 Identified as the Major Apelin Isoform in Human Plasma. Anal Biochem 2013, 442, 1–9.
  22. Yang, P.; Kuc, R.E.; Brame, A.L.; Dyson, A.; Singer, M.; Glen, R.C.; Cheriyan, J.; Wilkinson, I.B.; Davenport, A.P.; Maguire, J.J. Apelin-13(1–12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide Apelin-13. Front. Neurosci. 2017, 11, 92.
  23. Japp, A.G.; Newby, D.E. Unlocking the Therapeutic Potential of Apelin. Hypertension 2016, 68, 307–309.
  24. Brame, A.L.; Maguire, J.J.; Yang, P.; Dyson, A.; Torella, R.; Cheriyan, J.; Singer, M.; Glen, R.C.; Wilkinson, I.B.; Davenport, A.P. Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist. Hypertension 2015, 65, 834–840.
  25. Wang, W.; McKinnie, S.M.K.; Farhan, M.; Paul, M.; McDonald, T.; McLean, B.; Llorens-Cortes, C.; Hazra, S.; Murray, A.G.; Vederas, J.C.; et al. Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17. Hypertension 2016, 68, 365–377.
  26. Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.; Hsieh, F.; et al. Hydrolysis of Biological Peptides by Human Angiotensin-Converting Enzyme-Related Carboxypeptidase. J. Biol. Chem. 2002, 277, 14838–14843.
  27. McKinnie, S.M.K.; Fischer, C.; Tran, K.M.H.; Wang, W.; Mosquera, F.; Oudit, G.Y.; Vederas, J.C. The Metalloprotease Neprilysin Degrades and Inactivates Apelin Peptides. ChemBioChem 2016, 17, 1495–1498.
  28. Zhong, J.-C.; Zhang, Z.-Z.; Wang, W.; McKinnie, S.M.K.; Vederas, J.C.; Oudit, G.Y. Targeting the Apelin Pathway as a Novel Therapeutic Approach for Cardiovascular Diseases. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 1942–1950.
  29. De Hert, E.; Bracke, A.; Pintelon, I.; Janssens, E.; Lambeir, A.-M.; Van Der Veken, P.; De Meester, I. Prolyl Carboxypeptidase Mediates the C-Terminal Cleavage of (Pyr)-Apelin-13 in Human Umbilical Vein and Aortic Endothelial Cells. Int. J. Mol. Sci. 2021, 22, 6698.
  30. Fischer, C.; Lamer, T.; Wang, W.; McKinnie, S.M.K.; Iturrioz, X.; Llorens-Cortes, C.; Oudit, G.Y.; Vederas, J.C. Plasma Kallikrein Cleaves and Inactivates Apelin-17: Palmitoyl- and PEG-Extended Apelin-17 Analogs as Metabolically Stable Blood Pressure-Lowering Agents. Eur. J. Med. Chem. 2019, 166, 119–124.
  31. Galanth, C.; Hus-Citharel, A.; Li, B.; Llorens-Cortès, C. Apelin in the Control of Body Fluid Homeostasis and Cardiovascular Functions. Curr. Pharm. Des. 2012, 18, 789–798.
  32. Yang, P.; Read, C.; Kuc, R.E.; Buonincontri, G.; Southwood, M.; Torella, R.; Upton, P.D.; Crosby, A.; Sawiak, S.J.; Carpenter, T.A.; et al. Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension. Circulation 2017, 135, 1160–1173.
  33. Ronkainen, V.; Ronkainen, J.J.; Hänninen, S.L.; Leskinen, H.; Ruas, J.L.; Pereira, T.; Poellinger, L.; Vuolteenaho, O.; Tavi, P. Hypoxia Inducible Factor Regulates the Cardiac Expression and Secretion of Apelin. FASEB J. 2007, 21, 1821–1830.
  34. Sheikh, A.Y.; Chun, H.J.; Glassford, A.J.; Kundu, R.K.; Kutschka, I.; Ardigo, D.; Hendry, S.L.; Wagner, R.A.; Chen, M.M.; Ali, Z.A.; et al. In Vivo Genetic Profiling and Cellular Localization of Apelin Reveals a Hypoxia-Sensitive, Endothelial-Centered Pathway Activated in Ischemic Heart Failure. Am. J. Physiol.-Heart Circ. Physiol. 2008, 294, H88–H98.
  35. Guzelburc, O.; Demirtunc, R.; Altay, S.; Kemaloglu Oz, T.; Tayyareci, G. Plasma Apelin Level in Acute Myocardial Infarction and Its Relation with Prognosis: A Prospective Study. JRSM Cardiovasc. Dis. 2021, 10, 2048004020963970.
  36. Pauli, A.; Norris, M.L.; Valen, E.; Chew, G.-L.; Gagnon, J.A.; Zimmerman, S.; Mitchell, A.; Ma, J.; Dubrulle, J.; Reyon, D.; et al. Toddler: An Embryonic Signal That Promotes Cell Movement via Apelin Receptors. Science 2014, 343, 1248636.
  37. Chng, S.C.; Ho, L.; Tian, J.; Reversade, B. ELABELA: A Hormone Essential for Heart Development Signals via the Apelin Receptor. Dev. Cell 2013, 27, 672–680.
  38. Murza, A.; Sainsily, X.; Coquerel, D.; Côté, J.; Marx, P.; Besserer-Offroy, É.; Longpré, J.-M.; Lainé, J.; Reversade, B.; Salvail, D.; et al. Discovery and Structure–Activity Relationship of a Bioactive Fragment of ELABELA That Modulates Vascular and Cardiac Functions. J. Med. Chem. 2016, 59, 2962–2972.
  39. Couvineau, P.; Llorens-Cortes, C.; Iturrioz, X. Elabela/Toddler and Apelin Bind Differently to the Apelin Receptor. FASEB J. 2020, 34, 7989–8000.
  40. Huang, S.K.; Shin, K.; Sarker, M.; Rainey, J.K. Apela Exhibits Isoform- and Headgroup-Dependent Modulation of Micelle Binding, Peptide Conformation and Dynamics. Biochim. Et Biophys. Acta (BBA)-Biomembr. 2017, 1859, 767–778.
  41. Wang, Z.; Yu, D.; Wang, M.; Wang, Q.; Kouznetsova, J.; Yang, R.; Qian, K.; Wu, W.; Shuldiner, A.; Sztalryd, C.; et al. Elabela-Apelin Receptor Signaling Pathway Is Functional in Mammalian Systems. Sci. Rep. 2015, 5, 8170.
  42. Perjés, Á.; Kilpiö, T.; Ulvila, J.; Magga, J.; Alakoski, T.; Szabó, Z.; Vainio, L.; Halmetoja, E.; Vuolteenaho, O.; Petäjä-Repo, U.; et al. Characterization of Apela, a Novel Endogenous Ligand of Apelin Receptor, in the Adult Heart. Basic Res. Cardiol. 2016, 111, 2.
  43. Kuba, K.; Sato, T.; Imai, Y.; Yamaguchi, T. Apelin and Elabela/Toddler; Double Ligands for APJ/Apelin Receptor in Heart Development, Physiology, and Pathology. Peptides 2019, 111, 62–70.
  44. Coquerel, D.; Chagnon, F.; Sainsily, X.; Dumont, L.; Murza, A.; Côté, J.; Dumaine, R.; Sarret, P.; Marsault, É.; Salvail, D.; et al. ELABELA Improves Cardio-Renal Outcome in Fatal Experimental Septic Shock. Crit. Care Med. 2017, 45, e1139–e1148.
  45. Kuba, K.; Zhang, L.; Imai, Y.; Arab, S.; Chen, M.; Maekawa, Y.; Leschnik, M.; Leibbrandt, A.; Markovic, M.; Schwaighofer, J.; et al. Impaired Heart Contractility in Apelin Gene–Deficient Mice Associated With Aging and Pressure Overload. Circ. Res. 2007, 101, e32–e42.
  46. Perjés, Á.; Skoumal, R.; Tenhunen, O.; Kónyi, A.; Simon, M.; Horváth, I.G.; Kerkelä, R.; Ruskoaho, H.; Szokodi, I. Apelin Increases Cardiac Contractility via Protein Kinase Cε- and Extracellular Signal-Regulated Kinase-Dependent Mechanisms. PLoS ONE 2014, 9, e93473.
  47. Seo, K.; Parikh, V.N.; Ashley, E.A. Stretch-Induced Biased Signaling in Angiotensin II Type 1 and Apelin Receptors for the Mediation of Cardiac Contractility and Hypertrophy. Front. Physiol. 2020, 11, 181.
  48. Berry, M.F.; Pirolli, T.J.; Jayasankar, V.; Burdick, J.; Morine, K.J.; Gardner, T.J.; Woo, Y.J. Apelin Has In Vivo Inotropic Effects on Normal and Failing Hearts. Circulation 2004, 110 (Suppl. S1), II187–II193.
  49. Folino, A.; Montarolo, P.G.; Samaja, M.; Rastaldo, R. Effects of Apelin on the Cardiovascular System. Heart Fail. Rev. 2015, 20, 505–518.
  50. Peyronnet, R.; Bollensdorff, C.; Capel, R.A.; Rog-Zielinska, E.A.; Woods, C.E.; Charo, D.N.; Lookin, O.; Fajardo, G.; Ho, M.; Quertermous, T.; et al. Load-Dependent Effects of Apelin on Murine Cardiomyocytes. Prog. Biophys. Mol. Biol. 2017, 130, 333–343.
  51. Wang, C.; Du, J.-F.; Wu, F.; Wang, H.-C. Apelin Decreases the SR Ca 2+ Content but Enhances the Amplitude of i Transient and Contractions during Twitches in Isolated Rat Cardiac Myocytes. Am. J. Physiol.-Heart Circ. Physiol. 2008, 294, H2540–H2546.
  52. Mughal, A.; Sun, C.; O’Rourke, S.T. Activation of Large Conductance, Calcium-Activated Potassium Channels by Nitric Oxide Mediates Apelin-Induced Relaxation of Isolated Rat Coronary Arteries. J. Pharmacol. Exp. Ther. 2018, 366, 265–273.
  53. Sahinturk, S.; Demirel, S.; Ozyener, F.; Isbil, N. Apelin-13 Relaxes the Rat Thoracic Aorta via APJ, NO, AMPK, and Potassium Channels. Gen. Physiol. Biophys. 2021, 40, 427–434.
  54. Katugampola, S.D.; Maguire, J.J.; Matthewson, S.R.; Davenport, A.P. -(Pyr(1))Apelin-13 Is a Novel Radioligand for Localizing the APJ Orphan Receptor in Human and Rat Tissues with Evidence for a Vasoconstrictor Role in Man. Br. J. Pharmacol. 2001, 132, 1255–1260.
  55. Rikitake, Y. The Apelin/APJ System in the Regulation of Vascular Tone: Friend or Foe? J. Biochem. 2021, 169, 383–386.
  56. Sahinturk, S.; Demirel, S.; Ozyener, F.; Isbil, N. Vascular Functional Effect Mechanisms of Elabela in Rat Thoracic Aorta. Ann. Vasc. Surg. 2022, 84, 381–397.
  57. Helker, C.S.; Eberlein, J.; Wilhelm, K.; Sugino, T.; Malchow, J.; Schuermann, A.; Baumeister, S.; Kwon, H.-B.; Maischein, H.-M.; Potente, M.; et al. Apelin Signaling Drives Vascular Endothelial Cells toward a Pro-Angiogenic State. eLife 2020, 9, e55589.
  58. Wang, X.; Liang, G.; Guo, Q.; Cai, W.; Zhang, X.; Ni, J.; Tao, Y.; Niu, X.; Chen, S. ELABELA Improves Endothelial Cell Function via the ELA–APJ Axis by Activating the PI3K/Akt Signalling Pathway in HUVECs and EA.Hy926 Cells. Clin. Exp. Pharmacol. Physiol. 2020, 47, 1953–1964.
  59. Roberts, E.M.; Newson, M.J.F.; Pope, G.R.; Landgraf, R.; Lolait, S.J.; O’Carroll, A.-M. Abnormal Fluid Homeostasis in Apelin Receptor Knockout Mice. J. Endocrinol. 2009, 202, 453–462.
  60. Hu, G.; Wang, Z.; Zhang, R.; Sun, W.; Chen, X. The Role of Apelin/Apelin Receptor in Energy Metabolism and Water Homeostasis: A Comprehensive Narrative Review. Front. Physiol. 2021, 12, 632886.
  61. Xu, J.; Chen, L.; Jiang, Z.; Li, L. Biological Functions of Elabela, a Novel Endogenous Ligand of APJ Receptor. J. Cell Physiol. 2018, 233, 6472–6482.
  62. Brubaker, P.H.; Kalra, S. Selected Abstracts From Recent Publications in Cardiopulmonary Disease Prevention and Rehabilitation. J. Cardiopulm. Rehabil. Prev. 2016, 36, 140–144.
  63. Vaughan, A.S.; Coronado, F.; Casper, M.; Loustalot, F.; Wright, J.S. County-Level Trends in Hypertension-Related Cardiovascular Disease Mortality—United States, 2000 to 2019. J. Am. Heart Assoc. 2022, 11, e024785.
  64. Yildiz, M.; Oktay, A.A.; Stewart, M.H.; Milani, R.V.; Ventura, H.O.; Lavie, C.J. Left Ventricular Hypertrophy and Hypertension. Prog. Cardiovasc. Dis. 2020, 63, 10–21.
  65. Arendse, L.B.; Danser AH, J.; Poglitsch, M.; Touyz, R.M.; Burnett, J.C.; Llorens-Cortes, C.; Ehlers, M.R.; Sturrock, E.D. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacol. Rev. 2019, 71, 539–570.
  66. Santos, R.A.S.; Sampaio, W.O.; Alzamora, A.C.; Motta-Santos, D.; Alenina, N.; Bader, M.; Campagnole-Santos, M.J. The ACE2/Angiotensin-(1–7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1–7). Physiol. Rev. 2018, 98, 505–553.
  67. Sainsily, X.; Coquerel, D.; Giguère, H.; Dumont, L.; Tran, K.; Noll, C.; Ionescu, A.L.; Côté, J.; Longpré, J.-M.; Carpentier, A.; et al. Elabela Protects Spontaneously Hypertensive Rats From Hypertension and Cardiorenal Dysfunctions Exacerbated by Dietary High-Salt Intake. Front. Pharmacol. 2021, 12, 709467.
  68. Wysocka, M.B.; Pietraszek-Gremplewicz, K.; Nowak, D. The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer. Front. Physiol. 2018, 9, 557.
  69. Sato, T.; Suzuki, T.; Watanabe, H.; Kadowaki, A.; Fukamizu, A.; Liu, P.P.; Kimura, A.; Ito, H.; Penninger, J.M.; Imai, Y.; et al. Apelin Is a Positive Regulator of ACE2 in Failing Hearts. J. Clin. Investig. 2013, 123, 5203–5211.
  70. Zhang, Z.-Z.; Wang, W.; Jin, H.-Y.; Chen, X.; Cheng, Y.-W.; Xu, Y.-L.; Song, B.; Penninger, J.M.; Oudit, G.Y.; Zhong, J.-C. Apelin Is a Negative Regulator of Angiotensin II–Mediated Adverse Myocardial Remodeling and Dysfunction. Hypertension 2017, 70, 1165–1175.
  71. Abbasloo, E.; Najafipour, H.; Vakili, A. Chronic Treatment with Apelin, Losartan and Their Combination Reduces Myocardial Infarct Size and Improves Cardiac Mechanical Function. Clin. Exp. Pharmacol. Physiol. 2020, 47, 393–402.
  72. Tomek, J.; Bub, G. Hypertension-Induced Remodelling: On the Interactions of Cardiac Risk Factors. J. Physiol. 2017, 595, 4027–4036.
  73. Sato, T.; Kadowaki, A.; Suzuki, T.; Ito, H.; Watanabe, H.; Imai, Y.; Kuba, K. Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling. Int. J. Mol. Sci. 2019, 20, 239.
  74. Wang, W.; Shen, M.; Fischer, C.; Basu, R.; Hazra, S.; Couvineau, P.; Paul, M.; Wang, F.; Toth, S.; Mix, D.S.; et al. Apelin Protects against Abdominal Aortic Aneurysm and the Therapeutic Role of Neutral Endopeptidase Resistant Apelin Analogs. Proc. Natl. Acad. Sci. USA 2019, 116, 13006–13015.
  75. Song, J.; Zhang, Z.; Dong, Z.; Liu, X.; Liu, Y.; Li, X.; Xu, Y.; Guo, Y.; Wang, N.; Zhang, M.; et al. MicroRNA-122-5p Aggravates Angiotensin II-Mediated Myocardial Fibrosis and Dysfunction in Hypertensive Rats by Regulating the Elabela/Apelin-APJ and ACE2-GDF15-Porimin Signaling. J. Cardiovasc. Transl. Res. 2022, 15, 535–547.
  76. Lv, W.; Zhang, L.; Cheng, X.; Wang, H.; Qin, W.; Zhou, X.; Tang, B. Apelin Inhibits Angiotensin II-Induced Atrial Fibrosis and Atrial Fibrillation via TGF-Β1/Smad2/α-SMA Pathway. Front. Physiol. 2020, 11, 583570.
  77. Xu, C.; Wang, F.; Chen, Y.; Xie, S.; Sng, D.; Reversade, B.; Yang, T. ELABELA Antagonizes Intrarenal Renin-Angiotensin System to Lower Blood Pressure and Protects against Renal Injury. Am. J. Physiol. Renal Physiol. 2020, 318, F1122–F1135.
  78. Sato, T.; Sato, C.; Kadowaki, A.; Watanabe, H.; Ho, L.; Ishida, J.; Yamaguchi, T.; Kimura, A.; Fukamizu, A.; Penninger, J.M.; et al. ELABELA-APJ Axis Protects from Pressure Overload Heart Failure and Angiotensin II-Induced Cardiac Damage. Cardiovasc. Res. 2017, 113, 760–769.
  79. Hendrianus; Adiarto, S.; Prakoso, R.; Firdaus, I.; Indriani, S.; Rudiktyo, E.; Widyantoro, B.; Taofan, T.; Ambari, A.M.; Sukmawan, R. 10 A novel peptide elabela is associated with hypertension-related subclinical atherosclerosis. J. Hypertens. 2022, 40 (Suppl. S2), e3.
  80. Li, Y.; Yang, X.; Ouyang, S.; He, J.; Yu, B.; Lin, X.; Zhang, Q.; Tao, J. Declined Circulating Elabela Levels in Patients with Essential Hypertension and Its Association with Impaired Vascular Function: A Preliminary Study. Clin. Exp. Hypertens. 2020, 42, 239–243.
  81. Xie, H.; Luo, G.; Zheng, Y.; Hu, D.; Peng, F.; Xie, L. Lowered Circulating Apelin Is Significantly Associated with an Increased Risk for Hypertension: A Meta-Analysis. Clin. Exp. Hypertens. 2017, 39, 435–440.
  82. Baysal, S.S.; Pirat, B.; Okyay, K.; Bal, U.A.; Uluçam, M.Z.; Öztuna, D.; Müderrisoğlu, H. Treatment-Associated Change in Apelin Concentration in Patients with Hypertension and Its Relationship with Left Ventricular Diastolic Function. Anatol. J. Cardiol. 2017, 17, 125–131.
  83. Ma, Z.; Zhao, L.; Zhang, Y.; Zhong, J.; Yang, X. Declined ELABELA Plasma Levels in Hypertension Patients with Atrial Fibrillation: A Case Control Study. BMC Cardiovasc. Disord. 2021, 21, 390.
  84. Ma, Z.; Zhao, L.; Martin, S.; Zhang, Y.; Dong, Y.; Zhong, J.-C.; Yang, X.-C. Lower Plasma Elabela Levels in Hypertensive Patients With Heart Failure Predict the Occurrence of Major Adverse Cardiac Events: A Preliminary Study. Front. Cardiovasc. Med. 2021, 8, 638468.
  85. Yu, P.; Ma, S.; Dai, X.; Cao, F. Elabela Alleviates Myocardial Ischemia Reperfusion-Induced Apoptosis, Fibrosis and Mitochondrial Dysfunction through PI3K/AKT Signaling. Am. J. Transl. Res. 2020, 12, 4467–4477.
  86. Deng, J. Advanced Research on the Regulated Necrosis Mechanism in Myocardial Ischemia-Reperfusion Injury. Int. J. Cardiol. 2021, 334, 97–101.
  87. Wang, L.; Wang, N.; Zhang, W.; Cheng, X.; Yan, Z.; Shao, G.; Wang, X.; Wang, R.; Fu, C. Therapeutic Peptides: Current Applications and Future Directions. Signal Transduct Target Ther. 2022, 7, 48.
  88. Murza, A.; Besserer-Offroy, É.; Côté, J.; Bérubé, P.; Longpré, J.-M.; Dumaine, R.; Lesur, O.; Auger-Messier, M.; Leduc, R.; Sarret, P.; et al. C-Terminal Modifications of Apelin-13 Significantly Change Ligand Binding, Receptor Signaling, and Hypotensive Action. J. Med. Chem. 2015, 58, 2431–2440.
  89. Trân, K.; Murza, A.; Sainsily, X.; Coquerel, D.; Côté, J.; Belleville, K.; Haroune, L.; Longpré, J.-M.; Dumaine, R.; Salvail, D.; et al. A Systematic Exploration of Macrocyclization in Apelin-13: Impact on Binding, Signaling, Stability, and Cardiovascular Effects. J. Med. Chem. 2018, 61, 2266–2277.
  90. Trân, K.; Van Den Hauwe, R.; Sainsily, X.; Couvineau, P.; Côté, J.; Simard, L.; Echevarria, M.; Murza, A.; Serre, A.; Théroux, L.; et al. Constraining the Side Chain of C-Terminal Amino Acids in Apelin-13 Greatly Increases Affinity, Modulates Signaling, and Improves the Pharmacokinetic Profile. J. Med. Chem. 2021, 64, 5345–5364.
  91. Coquerel, D.; Delile, E.; Dumont, L.; Chagnon, F.; Murza, A.; Sainsily, X.; Salvail, D.; Sarret, P.; Marsault, E.; Auger-Messier, M.; et al. Gαi-Biased Apelin Analog Protects against Isoproterenol-Induced Myocardial Dysfunction in Rats. Am. J. Physiol.-Heart Circ. Physiol. 2021, 320, H1646–H1656.
  92. Juhl, C.; Els-Heindl, S.; Schönauer, R.; Redlich, G.; Haaf, E.; Wunder, F.; Riedl, B.; Burkhardt, N.; Beck-Sickinger, A.G.; Bierer, D. Development of Potent and Metabolically Stable APJ Ligands with High Therapeutic Potential. ChemMedChem 2016, 11, 2378–2384.
  93. Théroux, L.; Van Den Hauwe, R.; Trân, K.; Fournier, J.; Desgagné, M.; Meneboo, N.; Lavallée, A.; Fröhlich, U.; Côté, J.; Hollanders, C.; et al. Signaling Modulation via Minimal C-Terminal Modifications of Apelin-13. ACS Pharmacol. Transl. Sci. 2023, 6, 290–305.
  94. Studneva, I.; Shulzhenko, V.; Veselova, O.; Pisarenko, O. Protective Effects of a Modified Apelin-12 and Dinitrosyl Iron Complexes in Experimental Cardioplegic Ischemia and Reperfusion. J. Physiol. Biochem. 2018, 74, 283–290.
  95. Sidorova, M.; Studneva, I.; Bushuev, V.; Pal’keeva, M.; Molokoedov, A.; Veselova, O.; Ovchinnikov, M.; Pisarenko, O. -Apelin-12: Optimization of Solid-Phase Synthesis and Evaluation of Biological Properties in Vitro and in Vivo. Peptides 2020, 129, 170320.
  96. Gerbier, R.; Alvear-Perez, R.; Margathe, J.; Flahault, A.; Couvineau, P.; Gao, J.; De Mota, N.; Dabire, H.; Li, B.; Ceraudo, E.; et al. Development of Original Metabolically Stable Apelin-17 Analogs with Diuretic and Cardiovascular Effects. FASEB J. 2017, 31, 687–700.
  97. Flahault, A.; Keck, M.; Girault-Sotias, P.-E.; Esteoulle, L.; De Mota, N.; Bonnet, D.; Llorens-Cortes, C. LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-Dependent Mechanism. Front. Pharmacol. 2021, 12, 715095.
  98. McKinnie, S.M.K.; Wang, W.; Fischer, C.; McDonald, T.; Kalin, K.R.; Iturrioz, X.; Llorens-Cortes, C.; Oudit, G.Y.; Vederas, J.C. Synthetic Modification within the “RPRL” Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation. J. Med. Chem. 2017, 60, 6408–6427.
  99. Fernandez, K.X.; Fischer, C.; Vu, J.; Gheblawi, M.; Wang, W.; Gottschalk, S.; Iturrioz, X.; Llorens-Cortés, C.; Oudit, G.Y.; Vederas, J.C. Metabolically Stable Apelin-Analogues, Incorporating Cyclohexylalanine and Homoarginine, as Potent Apelin Receptor Activators. RSC Med. Chem. 2021, 12, 1402–1413.
  100. Fischer, C.; Lamer, T.; Fernandez, K.; Gheblawi, M.; Wang, W.; Pascoe, C.; Lambkin, G.; Iturrioz, X.; Llorens-Cortes, C.; Oudit, G.Y.; et al. Optimizing PEG-Extended Apelin Analogues as Cardioprotective Drug Leads: Importance of the KFRR Motif and Aromatic Head Group for Improved Physiological Activity. J. Med. Chem. 2020, 63, 12073–12082.
  101. Trân, K.; Murza, A.; Sainsily, X.; Delile, E.; Couvineau, P.; Côté, J.; Coquerel, D.; Peloquin, M.; Auger-Messier, M.; Bouvier, M.; et al. Structure–Activity Relationship and Bioactivity of Short Analogues of ELABELA as Agonists of the Apelin Receptor. J. Med. Chem. 2021, 64, 602–615.
  102. Yang, P.; Read, C.; Kuc, R.E.; Nyimanu, D.; Williams, T.L.; Crosby, A.; Buonincontri, G.; Southwood, M.; Sawiak, S.J.; Glen, R.C.; et al. A Novel Cyclic Biased Agonist of the Apelin Receptor, MM07, Is Disease Modifying in the Rat Monocrotaline Model of Pulmonary Arterial Hypertension. Br. J. Pharmacol. 2019, 176, 1206–1221.
  103. Murza, A.; Sainsily, X.; Côté, J.; Bruneau-Cossette, L.; Besserer-Offroy, É.; Longpré, J.-M.; Leduc, R.; Dumaine, R.; Lesur, O.; Auger-Messier, M.; et al. Structure–Activity Relationship of Novel Macrocyclic Biased Apelin Receptor Agonists. Org. Biomol. Chem. 2017, 15, 449–458.
  104. Tran, K.; Sainsily, X.; Côté, J.; Coquerel, D.; Couvineau, P.; Saibi, S.; Haroune, L.; Besserer-Offroy, É.; Flynn-Robitaille, J.; Resua Rojas, M.; et al. Size-Reduced Macrocyclic Analogues of -Apelin-13 Showing Negative Gαi Bias Still Produce Prolonged Cardiac Effects. J. Med. Chem. 2022, 65, 531–551.
  105. Ma, Y.; Ding, Y.; Song, X.; Ma, X.; Li, X.; Zhang, N.; Song, Y.; Sun, Y.; Shen, Y.; Zhong, W.; et al. Structure-Guided Discovery of a Single-Domain Antibody Agonist against Human Apelin Receptor. Sci. Adv. 2020, 6, eaax7379.
  106. Read, C.; Yang, P.; Kuc, R.E.; Nyimanu, D.; Williams, T.L.; Glen, R.C.; Holt, L.J.; Arulanantham, H.; Smart, A.; Davenport, A.P.; et al. Apelin Peptides Linked to Anti-serum Albumin Domain Antibodies Retain Affinity in Vitro and Are Efficacious Receptor Agonists in Vivo. Basic Clin. Pharmacol. Toxicol. 2020, 126, 96–103.
  107. Xi, Y.; Yu, D.; Yang, R.; Zhao, Q.; Wang, J.; Zhang, H.; Qian, K.; Shi, Z.; Wang, W.; Brown, R.; et al. Recombinant Fc-Elabela Fusion Protein Has Extended Plasma Half-Life Andmitigates Post-Infarct Heart Dysfunction in Rats. Int. J. Cardiol. 2019, 292, 180–187.
  108. Holt, L.J.; Basran, A.; Jones, K.; Chorlton, J.; Jespers, L.S.; Brewis, N.D.; Tomlinson, I.M. Anti-Serum Albumin Domain Antibodies for Extending the Half-Lives of Short Lived Drugs. Protein Eng. Des. Sel. 2008, 21, 283–288.
  109. Sahoo, S.; Kariya, T.; Ishikawa, K. Targeted Delivery of Therapeutic Agents to the Heart. Nat. Rev. Cardiol. 2021, 18, 389–399.
  110. Peng, Y.; Wang, Y.; Zhou, C.; Mei, W.; Zeng, C. PI3K/Akt/MTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front. Oncol. 2022, 12, 819128.
  111. Girault-Sotias, P.-E.; Gerbier, R.; Flahault, A.; de Mota, N.; Llorens-Cortes, C. Apelin and Vasopressin: The Yin and Yang of Water Balance. Front. Endocrinol. 2021, 12, 735515.
  112. Jahangirian, H.; Ghasemian Lemraski, E.; Webster, T.J.; Rafiee-Moghaddam, R.; Abdollahi, Y. A Review of Drug Delivery Systems Based on Nanotechnology and Green Chemistry: Green Nanomedicine. Int. J. Nanomed. 2017, 12, 2957–2978.
  113. Martinho, N.; Damgé, C.; Reis, C.P. Recent Advances in Drug Delivery Systems. J. Biomater. Nanobiotechnol. 2011, 2, 510–526.
  114. Serpooshan, V.; Sivanesan, S.; Huang, X.; Mahmoudi, M.; Malkovskiy, A.V.; Zhao, M.; Inayathullah, M.; Wagh, D.; Zhang, X.J.; Metzler, S.; et al. -Apelin-13 Delivery via Nano-Liposomal Encapsulation Attenuates Pressure Overload-Induced Cardiac Dysfunction. Biomaterials 2015, 37, 289–298.
  115. de Villiers, M.M.; Aramwit, P.; Kwon, G.S. (Eds.) Nanotechnology in Drug Delivery; Springer New York: New York, NY, USA, 2009.
  116. Fang, J.; Koh, J.; Fang, Q.; Qiu, H.; Archang, M.M.; Hasani-Sadrabadi, M.M.; Miwa, H.; Zhong, X.; Sievers, R.; Gao, D.; et al. Injectable Drug-Releasing Microporous Annealed Particle Scaffolds for Treating Myocardial Infarction. Adv. Funct. Mater. 2020, 30, 2004307.
  117. Almas, T.; Haider, R.; Malik, J.; Mehmood, A.; Alvi, A.; Naz, H.; Satti, D.I.; Zaidi, S.M.J.; AlSubai, A.K.; AlNajdi, S.; et al. Nanotechnology in Interventional Cardiology: A State-of-the-Art Review. IJC Heart Vasc. 2022, 43, 101149.
  118. Mitchell, M.J.; Billingsley, M.M.; Haley, R.M.; Wechsler, M.E.; Peppas, N.A.; Langer, R. Engineering Precision Nanoparticles for Drug Delivery. Nat. Rev. Drug Discov. 2021, 20, 101–124.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback